Belinostat (PXD 101) for the Treatment of Peripheral T-Cell Lymphoma (PTCL)

Belinostat (PXD 101) is a histone deacetylase (HDAC) inhibitor that is being investigated for the treatment of relapsed or refractory (R/R) peripheral T-cell lymphoma (PTCL).
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news

Related Links:

We report a severe nelarabine related neuropathy with quadriparesis and respiratory failure and excellent recovery. Diagnosis of stage III biphenotypic lymphoblastic lymphoma was made at 11 years of age in a previously healthy male who presented with supraclavicular lymphadenopathy.
Source: Neuromuscular Disorders - Category: Neurology Authors: Source Type: research
arta Halasa Vorinostat (SAHA), an inhibitor of class I and II of histone deacetylases, is the first histone deacetylase inhibitor (HDI) approved for the treatment of cutaneous T-cell lymphoma in 2006. HDIs are promising anticancer agents that inhibit the proliferation of many types of cancer cells including breast carcinoma (BC). BC is a heterogeneous disease with variable biological behavior, morphological features, and response to therapy. Although significant progress in the treatment of BC has been made, high toxicity to normal cells, serious side effects, and the occurrence of multi-drug resistance limit the effec...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
Source: Annals of Hematology - Category: Hematology Source Type: research
-Osorno Anaplastic large cell lymphoma (ALCL) is a subtype of CD30+ large T-cell lymphoma (TCL) that comprises ~2% of all adult non-Hodgkin lymphomas. Based on the presence/absence of the rearrangement and expression of anaplastic lymphoma kinase (ALK), ALCL is divided into ALK+ and ALK-, and both differ clinically and prognostically. This review focuses on the historical points, clinical features, histopathology, differential diagnosis, and relevant cytogenetic and molecular alterations of ALK- ALCL and its subtypes: systemic, primary cutaneous (pc-ALCL), and breast implant-associated (BIA-ALCL). Recent studies have i...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
Br J Dermatol. 2021 Sep 16. doi: 10.1111/bjd.20757. Online ahead of print.ABSTRACTPrimary cutaneous T-cell lymphomas (CTCL) 1 are characterized by cutaneous clonal accumulation of T cells. Mycosis fungoides (MF) is the most common subtype. MF typically progresses slowly from early patch-plaque stage to advanced forms with tumours, erythroderma, and eventually nodal/visceral involvement. Sézary syndrome is characterized by leukemic involvement, lymphadenopathy and erythroderma 2 .PMID:34528240 | DOI:10.1111/bjd.20757
Source: The British Journal of Dermatology - Category: Dermatology Authors: Source Type: research
CONCLUSION: Stage progression in MF is associated with Th2/Th9 polarization of malignant cells, activation of proliferation, survival, as well as increased genomic instability. Global transcriptomic changes in multiple lesions may be caused by hematogenous cell percolation between discrete skin lesions.PMID:34528236 | DOI:10.1111/bjd.20760
Source: The British Journal of Dermatology - Category: Dermatology Authors: Source Type: research
Neurolymphomatosis (NL) is a rare condition caused by the lymphomatous or leukemic infiltration of nerves and manifests as neuropathy. Most often, NL is associated with B-lineage non-Hodgkin lymphoma (NHL) and only infrequently occurs in conjunction with T- or NK-lineage NHL. Extranodal NK/T-cell lymphoma (ENKTL)-associated NL is exceedingly unusual, with only 9 cases described in the English language literature, in addition to our case. Diagnosis of NL is challenging, as the entity can mimic neuropathies of more common etiologies, and an adequate biopsy may be difficult to obtain. Timely diagnosis demands a high index of ...
Source: Acta Haematologica - Category: Hematology Source Type: research
Blood Cancer Journal, Published online: 16 September 2021; doi:10.1038/s41408-021-00549-6BCL-W expression associates with poor outcome in patients with peripheral T-cell lymphoma not otherwise specified
Source: Blood Cancer Journal - Category: Hematology Authors: Source Type: research
CONCLUSIONS.—: Incorporating clinical, morphologic, and immunophenotypic features usually provides sufficient evidence to reach a preliminary diagnosis of mature T-cell lymphoma. Molecular genetic studies can be very helpful for the final diagnosis and classification, especially in challenging cases. Some molecular genetic features have been found in breast implant-associated anaplastic large cell lymphoma, distinct from anaplastic large cell lymphoma, ALK negative. Immunohistochemical staining of 4 markers may enable further subtyping of peripheral T-cell lymphomas.PMID:34524423 | DOI:10.5858/arpa.2021-0143-RA
Source: Archives of Pathology and Laboratory Medicine - Category: Laboratory Medicine Authors: Source Type: research
EJNMMI Res. 2021 Sep 14;11(1):90. doi: 10.1186/s13550-021-00827-1.ABSTRACTBACKGROUND: Interim [18F]fluoro-deoxyglucose-positron emission tomography predicts outcome in peripheral T-cell lymphoma (PTCL). We compared two quantitative evaluation methods.METHODS: Interim scans from 43 patients with anaplastic lymphoma kinase-negative PTCL from the 'Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphomas' trial were re-analyzed by qPET (relating residual lymphoma-related uptake to liver uptake) and ∆SUVmax (relating interim scan to baseline scan). The endpoint was progression-free survival.RESULTS: qPE...
Source: Nuklearmedizin - Category: Radiology Authors: Source Type: research
More News: Lymphoma | Pharmaceuticals | T-cell Lymphoma